Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Zoetis Inc. ZTS

Healthcare — Drug Manufacturers Specialty & Generic
S&P 500 Member Dividend Champion (5y) Insider Buys (last 12m)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.89
Total sells
2.54
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — 3 — — — —
Sell — — — — 1 — — — — — — —
Insider Ownership
1.28%

Capital & Financial Ratios

Market Cap
30,050.00
Revenue
9,525.00
Net Income
2,637.00
Free Cash Flow
2,327.00
Net Debt
7,372.00
Current Ratio
3.08
Debt/Equity
2.87
P/E ratio
11.74
P/S ratio
3.13
P/B ratio
9.47
Past 5Y EPS Growth
11.91%
This Y EPS Growth
(2.45%)
Next Y EPS Growth
3.36%
Next 5Y EPS Growth
3.03%
in millions of $

Dividends

Payout Ratio
0.29
Annual Dividend Rate
1.50
Annual Dividend Yield
0.76%
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡
2026 2.12
—
—
—
2025 2.00
—
—
—
—
2024 1.73
—
—
—
—
2023 1.50
—
—
—
—
2022 1.30
—
—
—
—
2021 1.00
—
—
—
—
2020 0.80
—
—
—
—
2019 0.66
—
—
—
—
2018 0.50
—
—
—
—
2017 0.42
—
—
—
—
2016 0.38
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 2,041.00 1,987.00 2,312.00 1,676.00
Receivables 1,304.00 1,316.00 1,590.00 1,571.00
Inventory 2,564.00 2,306.00 2,430.00 2,574.00
Other 434.00 377.00 436.00 535.00
6,343.00 5,986.00 6,768.00 6,356.00
2023 2024 2025 Q'26
Payables 411.00 433.00 487.00 452.00
ST’ Debt 3.00 1,350.00 — —
Other 102.00 125.00 107.00 125.00
1,889.00 3,412.00 2,235.00 2,061.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 2,262.00 2,468.00 — —
—
’25 2,198.00 2,474.00 2,400.00 2,395.00
9,467.00
’24 2,190.00 2,361.00 2,388.00 2,317.00
9,256.00
’23 2,000.00 2,180.00 2,151.00 2,213.00
8,544.00
’22 1,986.00 2,052.00 2,002.00 2,040.00
8,080.00
’21 1,871.00 1,948.00 1,990.00 1,967.00
7,776.00
’20 1,534.00 1,548.00 1,786.00 1,807.00
6,675.00
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 401.00 655.00 — —
—
’25 515.00 605.00 891.00 893.00
2,904.00
’24 595.00 502.00 951.00 905.00
2,953.00
’23 549.00 183.00 724.00 897.00
2,353.00
’22 309.00 336.00 526.00 741.00
1,912.00
’21 400.00 481.00 653.00 679.00
2,213.00
’20 408.00 438.00 562.00 718.00
2,126.00
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 301.00 539.00 — —
—
’25 337.00 459.00 756.00 731.00
2,283.00
’24 456.00 370.00 784.00 688.00
2,298.00
’23 328.00 18.00 580.00 695.00
1,621.00
’22 194.00 190.00 372.00 571.00
1,327.00
’21 323.00 368.00 534.00 513.00
1,738.00
’20 334.00 351.00 443.00 566.00
1,694.00
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.42 1.65 — —
—
’25 1.41 1.61 1.63 1.37
6.02
’24 1.31 1.37 1.50 1.29
5.47
’23 1.19 1.45 1.29 1.14
5.07
’22 1.26 1.12 1.13 0.99
4.49
’21 1.17 1.07 1.16 0.87
4.27
’20 0.88 0.79 1.00 0.75
3.42

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 124.15 141.52 144.80 115.25 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 243.24 201.92 200.53 177.40 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13,800 14,100 13,800 14,500 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.59 0.61 0.67 0.65 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8,080.00 8,544.00 9,256.00 9,467.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 69.63% 70.03% 70.62% 71.84% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,656.00 2,936.00 3,133.00 3,360.00 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 32.87% 34.36% 33.85% 35.49% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,111.00 2,340.00 2,496.00 2,673.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 465.00 491.00 497.00 487.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.23 18.53 20.38 21.35 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 4.51 5.08 5.47 6.03 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.08 5.10 6.50 6.55 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.25) (1.59) (1.44) (1.40) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.83 3.52 5.06 5.15 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.39 10.82 10.50 7.51 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 468.89 461.17 454.20 443.44 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 32.56 38.77 29.73 20.87 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.52 10.61 8.00 5.89 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.64 18.16 15.51 16.34 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.06 11.14 8.49 6.73 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 55.15 58.72 34.20 27.92 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,912.00 2,353.00 2,953.00 2,904.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (585.00) (732.00) (655.00) (621.00) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,327.00 1,621.00 2,298.00 2,283.00 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4,339.00 4,454.00 2,574.00 4,533.00 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7,904.00 6,567.00 6,570.00 9,042.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4,323.00 4,526.00 4,583.00 6,730.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4,403.00 4,991.00 4,770.00 3,331.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.67% 16.05% 17.43% 18.00% ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.02% 19.28% 20.94% 20.87% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 47.26% 49.90% 50.94% 65.99% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Zoetis Inc. (ZTS), the world’s leading animal health company, showcases robust resilience and growth amid surging pet ownership and global livestock demands, with revenues surging 89% from $4.89 billion in 2016 to $9.26 billion in 2024 (8.3% CAGR). This momentum stems from a diversified portfolio in companion animals and livestock, enhanced by innovations like advanced diagnostics and dermatology therapies, alongside operational efficiency—revenue per employee hitting $671,000 and shares reduced 8.5% for shareholder value.

Profitability is accelerating, with gross margins expanding to 70.6%, EBT margins to 33.9%, and free cash flow per share tripling to $5.06, fueling dividends, buybacks, and high ROIC of 20.9%. Despite a solid balance sheet and manageable debt, recent stock dips—down 37% from peaks—have compressed valuations to attractive levels (PE ~30x, forward ~19x), signaling undervaluation amid analyst targets implying 15% mean upside and up to 56% potential.

Future catalysts include AI-driven diagnostics, biologics, and tailwinds from the $300B+ pet market by 2030, with EPS projected to reach $7.63 by 2028. Routine insider sells pose no red flags, positioning Zoetis for 20%+ annualized returns— a compelling buy-the-dip opportunity in the animal health revolution.

Read full commentary →

Zoetis Inc. (ZTS) Latest News

News by impact score

Fine-tune

8 Sep

3 , 10:51 AM
Zoetis shares declined following an earnings revision. Earnings revision triggered share price drop with moderate effect on near-term sentiment.

23 Aug

3 , 8:29 PM
Zoetis secures emergency authorization for Simparica Trio to counter slowing U.S. business. Product authorization may influence financial performance and competitive positioning but faces limits from broader U.S. slowdown.

3 , 3:49 PM
Zoetis earnings indicate a divided business, raising questions on whether its pipeline can restore growth. Divided earnings and pipeline prospects may moderately influence company performance outlook.

19 Aug

4 , 11:13 AM
Zoetis lowered its 2026 outlook and secured Simparica Trio EUA, raising questions over shifts in the company's investment case. Lowered 2026 guidance signals potential challenges to long-term growth and investor sentiment.

18 Aug

3 , 10:19 AM
Michael Burry has taken a bullish stance on Zoetis Inc. (ZTS), a beaten-down healthcare stock, raising the question of whether investors should buy. Michael Burry's bullish position on Zoetis may sway investor sentiment and produce moderate short-term market effects without altering core operations.

13 Aug

4 transcript www.fool.com, 8:01 AM
Zoetis (ZTS) released its Q2 2026 earnings call transcript covering financial results, guidance and executive commentary on operations. Quarterly earnings transcripts deliver key metrics and outlook that drive material shifts in valuation and sentiment.

3 stocktwits.com, 4:34 PM
FDA approves Zoetis dog pill against screwworm; ZTS stock rises on Michael Burry backing. FDA approval adds one veterinary product with limited scope relative to overall operations.

10 Aug

3 , 9:09 AM
Zoetis (ZTS) showed early promise but later encountered setbacks that hurt its performance and raised questions about strategy and results. Setbacks at Zoetis will likely produce moderate effects on operations and investor views without fully shifting long-term direction.

9 Aug

3 , 11:25 PM
Zoetis faces leadership changes and competitive pressures that are shaping its Q2 guidance and forward outlook. Leadership shifts combined with competitive pressures are adjusting Zoetis guidance and near-term positioning without indicating transformative change.

3 www.marketbeat.com, 2:03 PM
Zoetis Inc. reported Q2 financial results and discussed operational performance, product sales, and future guidance during its earnings call. Q2 earnings and guidance influence near-term investor views on revenue trends and profitability but do not signal major strategic shifts.

7 Aug

4 , 12:19 PM
Zoetis reported earnings followed by a guidance cut that raises questions over its current valuation. Guidance cut signals risks to projected growth and directly pressures future performance and investor sentiment.

4 transcript , 10:00 AM
Zoetis Inc.'s Q2 earnings call highlighted deeper pressure in the companion animal segment. Deeper companion animal pressure signals potential revenue challenges for Zoetis.

3 stocktwits.com, 7:58 PM
Michael Burry bought Zoetis Inc. (ZTS) shares as one of five investments that also include Freddie Mac, while noting chip shortages. Famed investor Michael Burry acquiring ZTS shares may temporarily lift market sentiment around the stock.

3 www.cfodive.com, 10:31 AM
Zoetis appoints GE Health CFO to dual roles of finance chief and COO. Executive hire for key dual finance and operations role may affect company leadership and strategy execution.

6 Aug

4 , 12:02 PM
Zoetis Q2 earnings beat estimates but revenues missed targets, leading the company to cut its 2026 outlook. Revenue shortfall plus reduced 2026 guidance signals notable pressure on future growth and investor sentiment.

4 , 9:27 AM
Zoetis Inc. (ZTS) missed Q2 CY2026 sales expectations. Missing quarterly sales forecasts typically triggers stock declines and shifts in growth outlook.

3 transcript , 7:16 PM
Zoetis Inc. (ZTS) addressed Q2 2026 earnings amid market headwinds through strategic initiatives. Earnings discussion of headwinds and strategies points to moderate effects on operations and sentiment.

3 transcript app.moby.co, 5:51 PM
Zoetis Inc. presented Q2 2026 financial results and operational highlights during its earnings call. Quarterly earnings releases typically drive short-term stock price moves for Zoetis without shifting long-term trajectory.

3 , 8:20 AM
Zoetis Inc. (ZTS) exceeded analyst expectations for its second-quarter earnings. Earnings beats typically drive short-term positive stock movement and sentiment.

3 , 7:00 AM
Zoetis Inc. reported second quarter 2026 financial results. Quarterly earnings releases deliver financial metrics that shape near-term investor views and valuation.

3 , 7:00 AM
Zoetis Inc. appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer. New CFO and COO appointments can influence financial strategy and operations but are unlikely to transform overall company direction.

3 Aug

4 , 11:16 PM
Michael Burry bets on Zoetis Inc. (ZTS) as the company advances its OA pipeline, directly shaping investor positions and stock trajectory. Burry's investment and OA pipeline progress point to major moves in company direction and market reaction.

3 www.barchart.com, 3:20 PM
Michael Burry doubles his stake in Zoetis Inc. (ZTS), reinforcing the bullish outlook for the animal health company's stock. Burry's increased position may lift short-term investor sentiment around Zoetis but leaves core operations unchanged.

3 , 11:52 AM
Zoetis Inc. (ZTS) prepares to release Q2 earnings with outlined expectations for revenue, earnings per share, and segment performance in animal health markets. Q2 earnings data directly informs near-term financial results and investor positioning for Zoetis.

3 , 10:20 AM
Zoetis (ZTS) growth weakens amid softening pet care demand. Softening pet care demand weakens Zoetis growth and may moderately affect its financial performance.

22 Jul

4 , 7:30 AM
Zoetis launches Portela (relfovetmab) in Canada and the European Union. Significant new product launch expands revenue streams in major markets.

3 , 10:13 AM
Zoetis Inc. launches two long-acting pet pain therapies in Canada and Europe. Regional product launches expand pet health offerings but remain limited in global scope.

16 Jul

3 www.barchart.com, 8:22 AM
Zoetis Inc. prepares to report quarterly earnings, with analysts forecasting EPS and revenue figures alongside expectations for animal health segment performance and margin trends. Earnings preview sets near-term expectations that can move ZTS shares but rarely alters long-term fundamentals.

15 Jul

3 , 8:30 AM
Zoetis launches Lenivia® (izenivetmab injection) in Canada and the European Union. New product launch expands Zoetis market access in Canada and EU.

14 Jul

4 www.semafor.com, 9:00 AM
Zoetis acquires a medical imaging company to advance its artificial intelligence development. Acquisition marks a major strategic expansion into AI medical imaging that can shift Zoetis competitive positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us